https://www.pfizer.com/news/press-releas...ne-results
NEW YORK AND MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)
today announced results from a Phase 2/3 trial showing
a favorable safety profile and robust neutralizing antibody responses
in children 5 to 11 years of age
using a two-dose regimen of 10 µg administered 21 days apart,
a smaller dose than the 30 µg dose used for people 12 and older
NEW YORK AND MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc.
(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX)
today announced results from a Phase 2/3 trial showing
a favorable safety profile and robust neutralizing antibody responses
in children 5 to 11 years of age
using a two-dose regimen of 10 µg administered 21 days apart,
a smaller dose than the 30 µg dose used for people 12 and older